These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Tolcapone for Parkinson's disease. Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124 [No Abstract] [Full Text] [Related]
14. Practical issues with COMT inhibitors in Parkinson's disease. Waters C Neurology; 2000; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511 [TBL] [Abstract][Full Text] [Related]
15. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Kaakkola S Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464 [TBL] [Abstract][Full Text] [Related]
16. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Schapira AH; Obeso JA; Olanow CW Neurology; 2000; 55(11 Suppl 4):S65-8; discussion S69-71. PubMed ID: 11147512 [TBL] [Abstract][Full Text] [Related]
17. What is new in movement disorders? Poewe W Wien Klin Wochenschr; 1999 Sep; 111(17):664-71. PubMed ID: 10526391 [TBL] [Abstract][Full Text] [Related]
18. [Entacapone in the therapy of Parkinson disease]. Teräväinen H Duodecim; 1999; 115(24):2734-44. PubMed ID: 11979613 [No Abstract] [Full Text] [Related]